Allergan plc. (AGN) surged 3.76% during the last session. The last traded price was up 8.24 points at $227.13. The data for the fund flow suggests that the net intraday money flow was $(-4.18) million. The fund value in upticks was recorded to be $240.23 million and in downticks, it was found to be $244.42 million. The up/down ratio for the day was measured to be 0.98. For the week, the shares have seen a percentage change of 6.53%.A block trade of $(-15.38) million in net money flow was also recorded during the day. For the block, the combined worth of upticks was $3.18 million and that of downticks was $18.56 million. The block tradeoff had the up/down ratio of 0.17.Block trades are executed by Investment Banking firms or Wealth Managers shifting positions or Day traders taking advantage of trading signals.
Shares of Allergan plc rose by 7.37% in the last five trading days and 9.19% for the last 4 weeks. Allergan plc is up 9.75% in the last 3-month period. Year-to-Date the stock performance stands at 9.19%. Allergan plc. (NYSE:AGN) rose 4.76% or 10.43 points on Wednesday and made its way into the gainers of the day. After trading began at $219 the stock was seen hitting $230.6045 as a peak level and $217.56 as the lowest level. The stock ended up at $229.32. The daily volume was measured at 6,637,165 shares. The 52-week high of the share price is $301.32 and the 52-week low is $184.5. The company has a market cap of $85,984 million.
Company has reported several Insider transactions to the SEC, on Dec 9, 2016, Nesli Basgoz (director) sold 500 shares at 188.72 per share price.On Nov 21, 2016, Brent L Saunders (CEO) purchased 5,250 shares at 189.13 per share price.On Nov 15, 2016, Maria Teresa Hilado (CFO) purchased 1,422 shares at 210.68 per share price.
Allergan plc Ordinary Shares Last issued its quarterly earnings results on Nov 2, 2016. The company reported $3.32 EPS for the quarter, missing the analyst consensus estimate by $ -0.23. Analyst had a consensus of $3.55. The company had revenue of $3622.00 million for the quarter, compared to analysts expectations of $3675.44 million. The companys revenue was up 4.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.48 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Allergan plc Ordinary Shares was Reiterated by Credit Suisse on Dec 9, 2016 to Outperform, Lowers Price Target to $ 274 from a previous price target of $301 .Allergan plc Ordinary Shares was Reiterated by Mizuho on Nov 17, 2016 to Buy, Lowers Price Target to $ 273 from a previous price target of $293 .
Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan plc, formerly known as Actavis plc, is headquartered in Dublin, Ireland.